Element Biosciences Advances into IVD and Proteomics with AVITI Platform and Strategic Partnerships

Source: Follow the Cause and Investigate the Medicine

On January 13, 2025, Element announced a collaboration agreement with Revvity (formerly PerkinElmer) to jointly advance sequencing-based in vitro diagnostic (IVD) testing for newborns.

This collaboration follows Revvity's recent launch of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and also strengthens Element's momentum toward obtaining regulatory approval for the benchtop AVITI sequencing system.

Currently, customers will be able to immediately access the RUO (Research Use Only) sequencing platform, Element AVITI.

This sentence needs to be translated from Chinese to Chinese:

First, the cooperation between the two parties has existed for a long time, and both sides are quite satisfied with it;

This dates back to March 15, 2024, when Revvity launched its newborn sequencing research solution.

Revvity integrates reagents, equipment, and software to provide customers with a comprehensive solution covering sample collection, sample management, DNA extraction, quality control, library preparation, sequencing, analysis, and interpretation.

Interestingly, the sequencing part is compatible with the Element AVITI system and other mainstream NGS platforms, as stated by Revvity.

Good grief, everything else has become something else.

Second, Element's sequencer is set to enter the IVD field.

"At the same time, it also strengthened Element's momentum to obtain regulatory approval for the AVITI benchtop sequencing system."

This statement may require some speculation; Element might have had certain hesitations about entering the IVD market previously.

Of course, this may just be hesitation about timing; the market definitely wants it.

Since it has such a high starting point, it is believed that Element is determined to enter the IVD market.

We must first understand, who are Element's target customers?

It must not be a large centralized sequencing customer like GeneDx or Tempus.

At least not for now.

The customer profile is either a medium-sized scientific research laboratory or a small-to-medium-sized research-oriented company.

Of course, the biggest one is the clinical needs of the medical system.

The sequencing needs of the medical system happen to meet Element's decentralized sequencing slogan, what a coincidence!

In addition, Element has higher sequencing quality, and the magical process captured by the Element Trinity sequencer greatly reduces the burden on medical system staff.

It seems that Element has already set up this situation long ago.

Compared to MGI's widespread success in clinical applications within China, the U.S. market remains less welcoming for Chinese companies.

There are both political and cultural factors at play.

What a coincidence, Element is domestic, you know.

Therefore, for Illumina, the threat from Element in China is far greater than that from MGI.

(Or just buy it)

In addition to IVD, Element announced a collaboration with Alamar Biosciences during JPM2025 to jointly advance end-to-end solutions in proteomics.

Hahaha, the series of proteomics is getting more and more exciting.

Regarding Alamar, we have talked about it before. If you are interested, you can go and check it out.

Boss, why don't we buy another one?

Finally, there is nothing to summarize, so let me leave you with a question:

If Element enters China, is there more potential in pursuing IVD registration or in proteomics?